ArticleScientific reports2026
Development of VP1 based indirect ELISAs for BK and JC polyomaviruses with seroprevalence assessment and cross reactivity evaluation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK virus (BKV) and JC virus (JCV) are widespread human polyomaviruses with significant clinical relevance, especially in immunocompromised populations. Reliable serological assays play a key role in epidemiological surveillance and clinical diagnostics. In this study, indirect ELISAs based on recombinant VP1 capsid proteins of BKV and JCV-expressed and purified using insect cell-based systems-were developed and optimized. A serological analysis of 67 human serum samples revealed an overall seroprevalence of 77.6% for BKV and 34.3% for JCV, with antibody prevalence increasing progressively with age. Importantly, competitive inhibition ELISAs demonstrated no significant cross-reactivity between antibodies against BKV and JCV VP1 antigens, confirming the high specificity of the assays. Comparative evaluation indicated that baculovirus-expressed VP1 antigens yielded higher quality proteins yielding stronger and more reliable assay signals, endorsing their use for large-scale seroepidemiological studies. These findings provide robust serological tools for accurate assessment of polyomavirus exposure and have potential clinical utility in monitoring populations at risk of polyomavirus-associated diseases, such as transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.